Anti-cytokine therapies in T1D: Concepts and strategies
Related Experiment Video
Updated: May 13, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Gerald T Nepom1, Mario Ehlers, Thomas Mandrup-Poulsen
1Benaroya Research Institute, 1201 Ninth Av, Seattle, WA 98101 USA.
Abstract:
Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
Related Concept Videos
Type I Diabetes II: Pathophysiology
Tumor Immunotherapy
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

